Muscular Dystrophy vs. Myasthenia Gravis: Key Differences
Muscular Dystrophy (MD)
Nature: Group of genetic disorders causing progressive muscle degeneration and weakness.
- Cause: Mutations in genes encoding structural muscle proteins (dystrophin, sarcoglycans, laminin, etc.).
- Inheritance: X-linked recessive (Duchenne, Becker), autosomal dominant (facioscapulohumeral), autosomal recessive (limb-girdle).
- Onset: Childhood (Duchenne) to adulthood (OPMD, some LGMD).
- Progression: Relentless, irreversible weakness. Respiratory and cardiac involvement common.
- Diagnosis: CK elevated (10–100×), genetic testing, muscle biopsy (dystrophic changes).
- Treatment: Corticosteroids (Duchenne), exon skipping, gene therapy (emerging), supportive care (PT, cardiac/respiratory monitoring).
Myasthenia Gravis (MG)
Nature: Autoimmune disorder impairing neuromuscular transmission.
- Cause: Antibodies against acetylcholine receptor (AChR, 85%), MuSK (5–10%), LRP4, or agrin.
- Onset: Bimodal—women 20s–30s, men 50s–60s. Can occur at any age.
- Hallmark: Fatigable weakness—worsens with activity, improves with rest.
- Common presentations: Ocular (ptosis, diplopia), bulbar (dysphagia, dysarthria), limb, respiratory.
- Diagnosis: AChR/MuSK antibodies, repetitive nerve stimulation, single-fiber EMG, edrophonium (Tensilon) test.
- Treatment: Pyridostigmine (AChE inhibitor), immunosuppressants (prednisone, azathioprine, mycophenolate), IVIG, plasma exchange, thymectomy (for thymoma or generalized MG).
Comparison at a Glance
| Feature | Muscular Dystrophy | Myasthenia Gravis |
|---|---|---|
| Etiology | Genetic | Autoimmune |
| Weakness pattern | Fixed, progressive | Fatigable, fluctuating |
| CK level | Markedly elevated | Normal or mildly elevated |
| Nerve conduction | Normal | Decrement on RNS |
| Treatment goal | Slow progression, manage complications | Symptom control, remission possible |
